TY - JOUR AU - Das, Millie AU - Wakelee, Heather PY - 2012 TI - Anti-angiogenic agents in Non-Small-Cell Lung Cancer (NSCLC): a perspective on the MONET1 (Motesanib NSCLC Efficacy and Tolerability) study JF - Journal of Thoracic Disease; Vol 4, No 6 (December 21, 2012): Journal of Thoracic Disease Y2 - 2012 KW - N2 - Since the discovery of the critical role played by angiogenesis in tumor growth and development (1), there has been increased interest in evaluating anti-angiogenic agents in the treatment of various malignancies, including non-small-cell lung cancer (NSCLC). Bevacizumab is a humanized monoclonal antibody to vascular endothelial growth factor (VEGF) and is approved for use in combination with chemotherapy in multiple countries for the treatment of patients with metastatic NSCLC. UR - https://jtd.amegroups.org/article/view/559